Therapeutic applications of ribozymes.
The demonstration that RNA can be cleaved by cis or trans ribozymes (catalytic RNAs, RNA enzymes) has potentially important therapeutic implications. Since their discovery in the 1980s, the biochemistry and conserved sequences of ribozymes have been well characterized. Ribozymes are effective modulators of gene expression because of their simple structure, sitespecific cleavage activity, and catalytic potential. The targets of ribozyme-mediated gene modulation have ranged from cancer cells to foreign genes that cause infectious diseases. Additional target sites for ribozymes are in initial phases of development and design. Ribozymes have been targeted against a myriad of genes, including oncogenes (ras, BCR-ABL, c-fos) and drug resistance genes, as well as the human immunodeficiency virus-type I genome. These ribozymes have cleaved the target RNAs in vitro and altered the cellular pathology. Currently, the therapeutic application of ribozymes to human diseases is limited by gene transfer systems. It is anticipated that ribozymes ultimately will play an important role in human gene therapy.
Kijima
H
H
Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Ishida
H
H
Ohkawa
T
T
Kashani-Sabet
M
M
Scanlon
K J
KJ
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D001483:Base Sequence; D015316:Genetic Therapy; D006801:Humans; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000628:therapy*; D016337:RNA, Catalytic / Q000378:metabolism / Q000627:therapeutic use*
D016337:RNA, Catalytic